Search company, investor...

Predict your next investment

Venture Capital
eshelmanventures.com

See what CB Insights has to offer

Investments

19

Portfolio Exits

5

About Eshelman Ventures

Fred Eshelman is the founder of Eshelman Ventures, an investment company primarily interested in private healthcare companies. He usually serves on the boards of portfolio companies. Previously he founded and served as CEO and Executive Chairman of Pharmaceutical Product Development (PPDI, NASDAQ) prior to the sale of the company to private equity interests.

Headquarters Location

319 N. 3rd Street Suite 301

Wilmington, North Carolina, 28401,

United States

910-558-6885

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Eshelman Ventures News

Sapience raises funding to advance cancer therapy programmes

Jun 1, 2022

New investor NexPoint led the financing round, which included participation from existing investors Eshelman Ventures, Bristol Myers Squibb, and Kingdon Capital. A convertible note, which was provided by The post Sapience raises funding to advance cancer therapy programmes appeared first on Pharmaceutical Business review.

Eshelman Ventures Investments

19 Investments

Eshelman Ventures has made 19 investments. Their latest investment was in Sapience Therapeutics as part of their Series B on May 5, 2022.

CBI Logo

Eshelman Ventures Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

5/31/2022

Series B

Sapience Therapeutics

$41M

No

1

3/31/2022

Series B

Incyclix Bio

$30M

Yes

4

12/19/2019

Series B

Kinnate Biopharma

$74.5M

No

6

7/24/2019

Series B

Subscribe to see more

$99M

Subscribe to see more

10

4/11/2019

Series A

Subscribe to see more

$99M

Subscribe to see more

10

Date

5/31/2022

3/31/2022

12/19/2019

7/24/2019

4/11/2019

Round

Series B

Series B

Series B

Series B

Series A

Company

Sapience Therapeutics

Incyclix Bio

Kinnate Biopharma

Subscribe to see more

Subscribe to see more

Amount

$41M

$30M

$74.5M

$99M

$99M

New?

No

Yes

No

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

1

4

6

10

10

Eshelman Ventures Portfolio Exits

5 Portfolio Exits

Eshelman Ventures has 5 portfolio exits. Their latest portfolio exit was Meryx on December 07, 2021.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

12/7/2021

Corporate Majority

$99M

2

12/3/2020

IPO

Subscribe to see more

$99M

Subscribe to see more

10

1/29/2018

IPO

Subscribe to see more

$99M

Subscribe to see more

10

1/25/2018

IPO

Subscribe to see more

$99M

Subscribe to see more

10

5/17/2017

IPO

Subscribe to see more

$99M

Subscribe to see more

10

Date

12/7/2021

12/3/2020

1/29/2018

1/25/2018

5/17/2017

Exit

Corporate Majority

IPO

IPO

IPO

IPO

Companies

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Acquirer

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

2

10

10

10

10

Eshelman Ventures Team

1 Team Member

Eshelman Ventures has 1 team member, including current Founder, Fred N. Eshelman.

Name

Work History

Title

Status

Fred N. Eshelman

Founder

Current

Name

Fred N. Eshelman

Work History

Title

Founder

Status

Current

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.